| Therapeutic | Moxetumomab |
| Target | CD22 |
| Heavy Chain | EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA |
| Light Chain | DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Fv Fusion |
| Isotype | na |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | NFD |
| Recorded Developmental Technology | CAT Phage Display |
| INN Year Proposed | 2009 |
| INN Year Recommended | 2010 |
| Companies Involved | National Cancer Institute (USA), AstraZeneca, M. D. Anderson Cancer Center, MedImmune, National Cancer Institute (USA) |
| Conditions Approved | Hairy cell leukaemia |
| Conditions Active | na |
| Conditions Discontinued | Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma, Precursor cell lymphoblastic leukaemia-lymphoma |
| Notes | na |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
